NCT02969252View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2015

Conditions
Healthy
Interventions
DRUG

Rifamycin SV-MMX® 600

Sponsors
All Listed Sponsors
lead

Cosmo Technologies Ltd

INDUSTRY

NCT02969252 - Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter